Authors
Simran Vaja, Jennifer L Dickson, Carolyn Horst, Monica L Mullin, Amyn Bhamani, Andrew Creamer, Helen Hall, Chuen R Khaw, Ruth Prendecki, Priyam Verghese, Sophie Tisi, John McCabe, Esther Arthur-Darwka, Neal Navani, Anand Devaraj, Arjun Nair, SUMMIT consortium, Sam M Janes, Allan Hackshaw
Published in
British journal of cancer. Aug 07, 2026. Epub Aug 07, 2026.
Abstract
Smokers are eligible for lung cancer screening using low dose CT (LDCT) if they have a sufficiently high risk of lung cancer. In England, for example, people are eligible if their estimated risk using either of two validated models (PLCOm2012 and Liverpool Lung Project) exceeds a certain threshold. Risk is often estimated using only cigarette consumption (duration and number per day), yet many smokers also use other cancer-causing tobacco products.
SUMMIT is a prospective cohort study of a LDCT screening service. We evaluated the impact of cigars, pipes, and cigarillos on lung cancer risk.
Among 13,000 participants who were current/former cigarette smokers, 511 (1 in 25) were also regular users of cigars, pipes, or cigarillos. The 5-year cumulative lung cancer incidence in people who currently smoked both types of tobacco products was 8.85%, versus 5.74% for cigarette only current smokers. Among these 511 participants, the percentage whose risk was below the screening eligibility threshold ignoring other tobacco products which then exceeded the threshold including these products was 0.6% using LLPv2, and 8.2% using PLCOm2012.
All tobacco consumption should be considered when determining screening eligibility to avoid missing those who can benefit from LDCT.
Clinicaltrials.gov no: NCT03934866.
PMID:
42567897
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0